期刊文献+

[R_1R_3IM]^+[BF_4]^-离子液体中链状纳米金的制备 被引量:1

Preparation of Gold Nanochains in 1-Butyl-3-Methylimidazolium Tetrafluoroborate Ionic Liquids
下载PDF
导出
摘要 以N-甲基咪唑和溴代正丁烷为起始原料,采用两步法合成了1-丁基-3-甲基咪唑四氟硼酸盐离子液体,并对所合成的离子液体做了红外光谱表征。在1-丁基-3-甲基咪唑四氟硼酸盐离子液体中,利用硼氢化钠还原氯金酸,制备了纳米金。紫外-可见光谱和透射电镜(TEM)试验结果表明,所制备的纳米金以链状为主。离子液体在纳米金制备过程中不仅起到了溶剂作用,还起到了修饰剂的作用。 1-butyl-3-methylimidazolium tetrafluoroborate ionic liquid ([BMLM]^+[BF4]^-) was synthesized using N-methylimidazole and 1-bromobutane as starting materials by two-step method. The obtained ionic liquid was characterized by IR spectra. Gold nanochains were prepared through the reduction of HAuCI4 by NaBH4 in [BMIM]^+[BF4]^-. UV-Vis spectra and TEM images reveal that the prepared nano gold is mainly chain-like. The ionic liquid not only acts as reaction medium but also as modifier in the preparation ofnano gold.
出处 《稀有金属材料与工程》 SCIE EI CAS CSCD 北大核心 2009年第8期1454-1457,共4页 Rare Metal Materials and Engineering
基金 江苏省2006年度省属高校自然科学重大基础研究项目(06KJA61019) 江苏省贵金属深加工技术及其应用重点建设实验室开放研究课题基金项目(SYGK0712) 江苏技术师范学院青年基金项目(KYY07028)
关键词 离子液体 纳米金 制备 ionic liquids gold nanoparticles preparation
  • 相关文献

参考文献18

  • 1Wasserscheid P, Keim W. Angewandte Chemie International Edition[J], 2000, 39:3772.
  • 2Earle M J, Seddon K R. PureAppl Chem[J], 2000, 72:1391.
  • 3Welton T. Chem Rev[J], 1999, 99:2071.
  • 4Hagiwara R, Ito Y..IFluorine Chem[J], 2000, 105:221.
  • 5Olivier H. JMol CatalA: Chem[J], 1999, 146:285.
  • 6Frens G. Nature Physical Science[J], 1973, 241(105): 20.
  • 7Glish G L, Evans N D, Murray R Wet al. Langmuir[J], 1998, 14(1): 17.
  • 8Li Yadong, Wang Xun, Zhuang Jing et al. Nature[J], 2005, 437(1): 121.
  • 9Chiang Chenli, Hsu Mengbor, Lai Longbiao. Journal of Solid State Chemistry[J], 2004, 177(11): 3891.
  • 10Sau T K, Murphy C J. Langmuir[J], 2005, 21(7): 2923.

同被引文献13

  • 1王传平,孙舒婷,张丽娜,陈欣,魏琴.光度分析法在药物分析中的研究与应用[J].分析测试技术与仪器,2007,13(3):169-173. 被引量:5
  • 2Ibrahim F,El-Din MK,Eid Ml,et al. Validated stability-indicating spectrofluorimetric methods for the determination of ebastine in pharmaceutical preparations.Chem Cent J,2011,5(1):11.
  • 3Mohie KS,Fawzia I,et al.Validated spectroflurimetric determination of some H1receptor antagonist drugs in pharmaceutical preparations through charge transfer complexation.J Fluoresc ,2012,22(1):175.
  • 4Kang W,Liu K-H,Ryu J Y,et al.Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry.J Chromatogr B,2004,813(1-2):75.
  • 5Feng S,Jiang J,Wang P.Simultaneous determination of ebastine and its active metabolite (carebastine) in human plasma Using LC-MS-MS.Chromatographia,2009,70(9-10):1417.
  • 6The sface food and drug administation bureau of sfandards(trial) YBH00972004.
  • 7Quijano G,Couvert A,Amrane A.Ionic liquids:applications and future trends in bioreactor technology.Bioresour Technol,2010,101(23):8923.
  • 8Hou TT,Zhu Xis.Ionic liquid surfactant sensitized spectroscopic method for the determination of zinc.J Mol Liq,2012,166:17.
  • 9Tong CL,Zhuo XJ,Liu WP,et al.Synchronous uorescence measurement of enrooxacin in the pharmaceutical formulation and its residue in milks based on the yttrium (III)-perturbed luminescence.Talanta,2010,82(5):1858.
  • 10王娜,肖亚平.第二代H1抗组胺类药物——依巴斯汀[J].化学通报,2008,71(1):40-43. 被引量:4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部